Arca
Skip to content

Chronic kidney disease (ckd)

Drug research and approvals for chronic kidney disease (ckd): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 434 studies of chronic kidney disease (ckd) are recruiting on ClinicalTrials.gov, Health Canada has authorized 45 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 10 authorised medicines for it.

  • Recruiting worldwide: 434
  • Trials authorized in Canada: 45
  • FDA orphan approvals: 1
  • EU medicines: 10

Recruiting Now

Newest start dates first, of 434 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 45; search them all in Canada trials
Nov 13, 2026A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and…EPRA-0322EPOK THERAPEUTICS INC.Pending
Jul 30, 2026A phase III, randomised, double-blind, study to evaluate the effect of balcinrenone/dapagliflozin compared with dapagliflozin on renal and cardiovascular…BALCINRENONE-DAPAGLIFLOZIN (AZD2961) / DAPAGLIFLOZINAstraZeneca Pharmaceuticals LPOngoing
May 12, 2026A phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the effect of elecoglipron in reducing renal outcomes…ELECOGLIPRON (AZD5004) / DAPAGLIFLOZINAstraZeneca Pharmaceuticals LPOngoing
Nov 12, 2025A phase IIb, randomised, multicentre, double-blind study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat on…BAXDROSTAT / DAPAGLIFLOZINAstraZeneca Pharmaceuticals LPOngoing
Sep 22, 2025A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of orforglipron on the incidence of major adverse…ORFORGLIPRON (LY3502970)Eli LillyOngoing
Jul 30, 2025A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets…EMPAGLIFLOZINBOEHRINGER INGELHEIM (CANADA) LTD LTEEOngoing
Oct 15, 2024A phase III, randomised, double-blind, placebo-controlled, event-driven study to assess the efficacy, safety and tolerability of baxdrostat in combination with…BAXDROSTAT / DAPAGLIFLOZINAstraZeneca Pharmaceuticals LPOngoing
Jun 6, 2024Studies of heart & kidney protection with bi 690517 in combination with empagliflozin: a multicenter, international, randomized, double-blind,…VICADROSTAT (BI 690517) / EMPAGLIFLOZINBoehringer Ingelheim Pharmaceuticals, Inc.Ongoing
Apr 8, 2024An 18-month, open-label, single-arm safety extension study of an age- and bodyweight-adjusted oral finerenone regimen, in addition to an acei or arb, for the…FINERENONE (BAY-94-8862)BayerOngoing
Apr 4, 2024A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of retatrutide on the incidence of major adverse…RETATRUTIDE (LY3437943)Eli LillyOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 18, 2016ZemplarIndicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism…Abbvie, inc.Approved
Sep 7, 2016cinacalcetTreatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysisAmgen, Inc.Designated
Apr 3, 2009vonapanitasePrevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving…Proteon Therapeutics, Inc.Designated

Medicines Authorised in the EU

Newest first
May 29, 2026BopediatfurosemideProveca Pharma LimitedEMA ↗
Jun 11, 2025Xoanacylferric citrate coordination complexAveroaEMA ↗
Apr 24, 2023VafseovadadustatMedice Arzneimittel Pütter GmbH & Co. KGEMA ↗
Apr 25, 2022KapruviadifelikefalinVifor Fresenius Medical Care Renal Pharma FranceEMA ↗
Feb 16, 2022KerendiafinerenoneBayer AGEMA ↗
Aug 18, 2021EvrenzoroxadustatAstellas Pharma Europe B.V.EMA ↗
Nov 11, 2016ParsabivetelcalcetideAmgen Europe B.V.EMA ↗
May 27, 2015JinarctolvaptanOtsuka Pharmaceutical Netherlands B.V.EMA ↗
Aug 26, 2014Velphorosucroferric oxyhydroxideVifor Fresenius Medical Care Renal Pharma FranceEMA ↗
Jul 20, 2007Mirceramethoxy polyethylene glycol-epoetin betaRoche Registration GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.